6575 Share Price Performance
NT$0
0.00 (0.00%)
Price NT$0
Share Pricen/a
SyneuRx International (Taiwan) Corp. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
6575 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
SyneuRx International (Taiwan) Corp. Key Details
About 6575
- Founded
- 2013
- Employees
- n/a
- CEO
- WebsiteView website
SyneuRx International (Taiwan) Corp., a clinical-stage biotech company, develops drugs for the treatment of unmet medical needs in central nervous system disorders in Taiwan. Its pipeline includes Pentarlandir, which is in Phase II clinical trials for COVID-19; Airnecflu that is in Phase I clinical trials for COVID-19; NaBen, which is in Phase III clinical trials for adult schizophrenia, as well as in Phase II clinical trials adolescent schizophrenia; ClozaBen that is in Phase II clinical trials for refractory schizophrenia; NaBen, which is in Phase II clinical trials for early dementia; Tannquilynne that is in Phase II clinical trials for dementia and psychosis; Synapsinae, which is in Phase II clinical trials for early dementia and psychosis; and Synxyrin that is in Phase II clinical trials for early TRD and suicidality. SyneuRx International (Taiwan) Corp. was founded in 2013 and is based in New Taipei City, Taiwan.
